Chennai-based LifeCell International, India’s largest umbilical cord stem cell bank is looking at raising funds for its new venture public stem cell banking. The company said the funds will be used for infrastructure, expansion and marketing.
The public stem cell banking—which will allow anyone to receive stem cells that match their requirements from a storage facility—is being implemented through LifeCell Foundation, a non-profit venture.
LifeCell has already raised Rs 18 crore. Of this, Shriram group chairman R Thiagarajan, one of the promoters of LifeCell, has contributed Rs 2.5 crore and Mayur Abhaya, MD & CEO of LifeCell, has given 2.5 crore
International Stem Cell Corporation, announced today its wholly-owned subsidiary, Lifeline Cell Technology (Lifeline), has signed a distribution agreement with Tokyo-based Veritas Corporation to distribute its human cell culture products throughout Japan.
Lifeline, located in Maryland and California, specializes in the development, manufacture, and distribution of products to culture human cells for the study of human disease, including products to culture primary human cells and human stem cells. These products are being requested by customers overseas, including customers in Japan, Korea and India and this agreement is the first step in Lifeline’s plan to meet these requests.
Ashok Chakravarti remembers the moment he went blind.
It was on February 18, 2002. He was at work, at a chemical plant, when a pipe carrying sodium hydroxide (caustic soda) started to leak.
“I was fixing the leak when the chemical splashed into my eyes,” he says. The accident damaged the outermost layer of his eyes, the cornea.
Chakravarti is among thousands of Indians who lose their sight in chemical accidents each year.
Today, some of those people can see again, thanks to scientists at the L.V. Prasad Eye Institute, in Hyderabad.
The institute is treating patients with stem cells – not the controversial